Attorneys representing plaintiffs in the Dupixent (dupilumab) multidistrict litigation are seeking leadership positions in the consolidated proceedings, a procedural step that signals the case is moving toward coordinated pretrial workup in federal court.

The litigation centers on allegations that Sanofi and Regeneron, the manufacturers of Dupixent, failed to adequately warn patients and physicians about potential cancer risks associated with the biologic, including claims involving lymphoma and other malignancies. Plaintiffs allege the companies knew or should have known about the risk and did not communicate it through labeling or marketing.

Dupilumab is a fully human monoclonal antibody that inhibits interleukin-4 and interleukin-13 signaling. The FDA approved it in 2017 for moderate-to-severe atopic dermatitis in adults, and the indication set has since expanded to include pediatric atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyposis, eosinophilic esophagitis, and prurigo nodularis. It has become one of the most widely prescribed biologics in dermatology.

The multidistrict litigation consolidates individual product liability suits filed in federal courts around the country before a single judge for coordinated pretrial proceedings, including discovery, bellwether trial selection, and Daubert challenges to expert testimony. The leadership applications now before the court typically come from attorneys with prior experience steering large pharmaceutical caseloads, and the appointments will shape how the plaintiffs' case is argued through those early, often decisive stages.

For dermatology clinicians, the litigation raises familiar questions about risk communication for widely used immunomodulators. The complaints allege the manufacturers' warnings understated the cancer signal; the companies have not conceded any causal link, and the litigation remains at a procedural stage well before any findings on scientific merit. No recall has been issued, and Dupixent remains on the market under its existing approvals.

The court is expected to rule on the leadership appointments in the coming weeks, after which the MDL will move into consolidated discovery addressing regulatory filings, internal company documents, and the epidemiological evidence plaintiffs say supports the cancer claims.